tradingkey.logo

Bausch + Lomb Corp

BLCO
17.000USD
+0.615+3.75%
Cierre 02/06, 16:00ETCotizaciones retrasadas 15 min
6.02BCap. mercado
PérdidaP/E TTM

Bausch + Lomb Corp

17.000
+0.615+3.75%

Más Datos de Bausch + Lomb Corp Compañía

Bausch + Lomb Corporation is an eye health company. It operates through three segments: Vision Care, Pharmaceuticals, and Surgical. Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices for cataract surgery. Its brands consist of PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, ScoutPro, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, INFUSE, and many more.

Información de Bausch + Lomb Corp

Símbolo de cotizaciónBLCO
Nombre de la empresaBausch + Lomb Corp
Fecha de salida a bolsaMay 06, 2022
Director ejecutivoSaunders (Brenton L)
Número de empleados13500
Tipo de seguridadOrdinary Share
Fin del año fiscalMay 06
Dirección520 Applewood Crescent
CiudadVAUGHAN
Bolsa de valoresNASDAQ OMX NASDAQ Basic NYSE
PaísCanada
Código postalL4K 4B4
Teléfono19082552864
Sitio Webhttps://ir.bausch.com/
Símbolo de cotizaciónBLCO
Fecha de salida a bolsaMay 06, 2022
Director ejecutivoSaunders (Brenton L)

Ejecutivos de Bausch + Lomb Corp

Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Luc Bonnefoy
Mr. Luc Bonnefoy
President - Surgical
President - Surgical
77.36K
+6146.00%
Dr. Yehia Hashad, M.D.
Dr. Yehia Hashad, M.D.
Executive Vice President - Research & Development, Chief Medical Officer
Executive Vice President - Research & Development, Chief Medical Officer
68.18K
+17715.00%
Mr. Russel C. Robertson
Mr. Russel C. Robertson
Independent Director
Independent Director
66.56K
+1642.00%
Karen Ling ,
Karen Ling ,
Independent Director
Independent Director
52.37K
+35034.00%
Mr. Sam A. Eldessouky
Mr. Sam A. Eldessouky
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Mr. Thomas W. Ross, Sr.
Mr. Thomas W. Ross, Sr.
Lead Independent Director
Lead Independent Director
--
--
Mrs. Nathalie Bernier
Mrs. Nathalie Bernier
Independent Director
Independent Director
--
--
Dr. Andrew Charles Von Eschenbach, M.D.
Dr. Andrew Charles Von Eschenbach, M.D.
Independent Director
Independent Director
--
--
Ms. Sarah B. Kavanagh
Ms. Sarah B. Kavanagh
Independent Director
Independent Director
--
--
Mr. John A. Paulson ,
Mr. John A. Paulson ,
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Luc Bonnefoy
Mr. Luc Bonnefoy
President - Surgical
President - Surgical
77.36K
+6146.00%
Dr. Yehia Hashad, M.D.
Dr. Yehia Hashad, M.D.
Executive Vice President - Research & Development, Chief Medical Officer
Executive Vice President - Research & Development, Chief Medical Officer
68.18K
+17715.00%
Mr. Russel C. Robertson
Mr. Russel C. Robertson
Independent Director
Independent Director
66.56K
+1642.00%
Karen Ling ,
Karen Ling ,
Independent Director
Independent Director
52.37K
+35034.00%
Mr. Sam A. Eldessouky
Mr. Sam A. Eldessouky
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Mr. Thomas W. Ross, Sr.
Mr. Thomas W. Ross, Sr.
Lead Independent Director
Lead Independent Director
--
--

Desglose de ingresos

Divisa: USDActualizado: mar., 6 de ene
Divisa: USDActualizado: mar., 6 de ene
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Por negocioUSD
Nombre
Ganancia
Proporción
Devices
484.00M
37.78%
OTC
454.00M
35.44%
Pharmaceuticals
280.00M
21.86%
Branded and other Generics
59.00M
4.61%
Other revenues
4.00M
0.31%
La empresa aún no ha revelado los datos relevantes.
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Devices
484.00M
37.78%
OTC
454.00M
35.44%
Pharmaceuticals
280.00M
21.86%
Branded and other Generics
59.00M
4.61%
Other revenues
4.00M
0.31%

Estadísticas de accionistas

Actualizado: sáb., 22 de nov
Actualizado: sáb., 22 de nov
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Bausch Health Companies Inc
87.62%
Icahn Enterprises LP
0.99%
Deutsche Bank Securities Inc.
0.99%
Alberta Investment Management Corporation
0.92%
Oaktree Capital Management, L.P.
0.92%
Otro
8.56%
Accionistas
Accionistas
Proporción
Bausch Health Companies Inc
87.62%
Icahn Enterprises LP
0.99%
Deutsche Bank Securities Inc.
0.99%
Alberta Investment Management Corporation
0.92%
Oaktree Capital Management, L.P.
0.92%
Otro
8.56%
Tipos de accionistas
Accionistas
Proporción
Corporation
87.62%
Hedge Fund
3.73%
Investment Advisor/Hedge Fund
3.02%
Research Firm
1.67%
Investment Advisor
1.62%
Holding Company
0.99%
Sovereign Wealth Fund
0.92%
Individual Investor
0.48%
Family Office
0.24%

Participación institucional

Actualizado: lun., 8 de dic
Actualizado: lun., 8 de dic
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
247
42.63M
17.16%
+11.66K
2025Q3
260
42.62M
19.43%
+3.57M
2025Q2
253
39.09M
18.05%
+715.03K
2025Q1
249
38.33M
16.53%
-19.93M
2024Q4
239
35.61M
16.96%
-2.09M
2024Q3
234
37.72M
16.36%
-3.49M
2024Q2
237
40.61M
17.42%
+3.09M
2024Q1
226
37.49M
18.08%
-25.96M
2023Q4
216
38.90M
17.69%
-4.13M
2023Q3
198
43.02M
17.49%
-1.91M
Ver más

Actividad de los accionistas

Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Bausch Health Companies Inc
310.45M
87.65%
--
--
Mar 24, 2025
Icahn Enterprises LP
3.50M
0.99%
--
--
Sep 30, 2025
Deutsche Bank Securities Inc.
3.50M
0.99%
+89.90K
+2.64%
Sep 30, 2025
Alberta Investment Management Corporation
3.27M
0.92%
+258.00K
+8.58%
Mar 31, 2025
Oaktree Capital Management, L.P.
3.25M
0.92%
+724.19K
+28.72%
Sep 30, 2025
GoldenTree Asset Management, LP
2.66M
0.75%
+77.32K
+2.99%
Sep 30, 2025
D. E. Shaw & Co., L.P.
2.61M
0.74%
--
--
Sep 30, 2025
Silver Point Capital, L.P.
2.56M
0.72%
+2.56M
--
Sep 30, 2025
Fidelity Management & Research Company LLC
1.56M
0.44%
+788.29K
+102.13%
Sep 30, 2025
Glenview Capital Management, LLC
1.55M
0.44%
--
--
Sep 30, 2025
Ver más

ETFs relacionados

Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
Ballast Small/Mid Cap ETF
1.4%
Invesco RAFI Developed Mkts ex-US SM ETF
0.03%
BNY Mellon US Small Cap Core Equity ETF
0.03%
Schwab Fundamental International Small Equity ETF
0%
Goldman Sachs MarketBeta US 1000 Equity ETF
0%
Invesco Zacks Mid-Cap ETF
0%
QRAFT AI-Enhanced US Large Cap ETF
0%
AltShares Event-Driven ETF
0%
DFA Dimensional International Core Equity 2 ETF
0%
BNY Mellon US Mid Cap Core Equity ETF
0%
Ver más
Ballast Small/Mid Cap ETF
Proporción1.4%
Invesco RAFI Developed Mkts ex-US SM ETF
Proporción0.03%
BNY Mellon US Small Cap Core Equity ETF
Proporción0.03%
Schwab Fundamental International Small Equity ETF
Proporción0%
Goldman Sachs MarketBeta US 1000 Equity ETF
Proporción0%
Invesco Zacks Mid-Cap ETF
Proporción0%
QRAFT AI-Enhanced US Large Cap ETF
Proporción0%
AltShares Event-Driven ETF
Proporción0%
DFA Dimensional International Core Equity 2 ETF
Proporción0%
BNY Mellon US Mid Cap Core Equity ETF
Proporción0%

Dividendos

Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos

División de acciones

Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
KeyAI